Data Demonstrate Impact of Weight Loss with Sibutramine on Cardiovascular Risk Factors for Obese Patients
"Cardiovascular-related conditions including hypertension, dyslipidaemia and type 2 diabetes are all serious risks for obese patients," stated Professor Arya M. Sharma M.D., Ph.D., Professor of Medicine, Cardiovascular Obesity Research and Management, at McMaster University in Hamilton, Ontario, Canada. "These data are significant because they provide insight into the reduction of cardiovascular risk factors for these obese patients with sibutramine-induced weight loss."
Beneficial Effects in Obese Patients with Metabolic Syndrome
The majority of obese patients have metabolic syndrome, a condition defined by the presence of three or more cardiovascular risk factors, which include increased abdominal fat (measured by waist circumference), dyslipidaemia (elevated triglyceride levels and reduced HDL cholesterol, typically known as the 'good' cholesterol), hypertension and impaired fasting glucose.
Analyses of data from obese patients with metabolic syndrome who participated in five clinical trials with sibutramine and a reduced-calorie diet showed that after 12 months of therapy, 58 percent no longer met the criteria for a metabolic syndrome diagnosis (compared to 40 percent of placebo patients p
Date demonstra impactul pierdere în greutate, cu Sibutramine pe cardiovasculare, factori de risc pentru pacienþii obezi - Data Demonstrate Impact of Weight Loss with Sibutramine on Cardiovascular Risk Factors for Obese Patients - articole medicale engleza - startsanatate